Navigation Links
PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012
Date:9/18/2009

INCLINE VILLAGE, Nev., Sept. 18 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the "Notes"). The conversion rate, as adjusted, is 94.447 shares of common stock per $1,000 principal amount of the Notes, effective September 18, 2009. The conversion rate for the Notes was previously 89.165 shares of common stock per $1,000 principal amount of the Notes.

On March 2, 2009, PDL announced a cash dividend of $0.50 per share of its common stock, payable to stockholders of record on September 17, 2009. In connection with the cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding September 15, 2009, the ex-dividend date for the cash dividend, and the denominator of which is the difference of such average closing price less $0.50.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering
2. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
3. Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting.
4. Helix BioPharma Closes Private Placement
5. PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million
6. Helix BioPharma Announces $13.5 Million Private Placement
7. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
8. DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
9. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
10. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Mich. , May 26, 2016  Agriculture nutrients ... Des Moines, Iowa is running their ... Lake Erie and coastal regions ... key to preventing this widespread issue. NECi ... Upper Peninsula, developed a new, easy to ...
(Date:5/26/2016)... , May 26, 2016 Q BioMed ... it will be a featured presenter at the 5th Annual ... New York City at the Grand Hyatt ... , Q BioMed Inc. CEO, is scheduled to begin at ... the company,s business strategy, recent developments and outline milestones for ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several ... Inc. at the City of Knowledge in Panama, a 6 year-old Duchenne’s ... the US earlier this year following FDA approval of a second application for ...
(Date:5/26/2016)... ... 26, 2016 , ... FireflySci has been manufacturing quartz and ... over the globe. Their cute firefly logo has been spreading to more and ... spectrophotometer calibration standards that never require recalibration. These revolutionary standards have changed ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):